AnalyzeDirect

Niek F. Casteleijn^1,2, A. Lianne Messchendorp^1,2, Kyong T. Bae³, Eiji Higashihara⁴, Peter Kappert^2,5, Vicente Torres⁶, Esther Meijer^1,2, Anna M. Leliveld^2,7. Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients. Clinical and Experimental Nephrology. 23 June 2016.

Publication Date
June 2016

How Analyze was Used
“Total kidney volume was assessed using Analyze 8.0 software (AnalyzeDirect, Inc., Overland Park, KS,
USA)”

Keywords
Autosomal dominant polycystic kidney disease,
Tolvaptan,
Polyuria,
Ureter

Author Affiliation(s)
¹From the Department of Internal Medicine, Division of Nephrology and Hypertension (A.E., A.S., H.T., S.M.H., J.R.W., S.C.T., L.O.L.) and Division of Cardiovascular Diseases (A.L., L.O.L.), Mayo Clinic, Rochester, MN.

¹Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
²Expertise Center for Polycystic Kidney Disease, Groningen, The Netherlands
³Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
⁴Department of Urology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan
⁵Department of Radiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
⁶Department of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
⁷Department of Urology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Tags: ADPKD, Autosomal Dominant Polycystic Kidney Disease, Polyuria, Tolvaptan, Ureter